|
Natera, Inc., a global leader in cell-free DNA and precision medicine, announced a new Signatera collaboration with Angiex, Inc., a privately held biotech company developing a portfolio of Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs).
Angiex is conducting a phase I clinical trial of AGX101, an investigational TM4SF1-directed ND-ADC. AGX101 is designed to bind TM4SF1 and deliver a cytotoxic payload to TM4SF1-expressing tumour cells and tumour-associated endothelial cells. This dual-targeting approach is intended to address both tumour cells and tumour vasculature.
The trial is currently enrolling patients with unresectable, locally advanced or metastatic solid tumours. The collaboration will include longitudinal Signatera testing for circulating tumour DNA (ctDNA) to explore its value for treatment response monitoring during AGX101 treatment.
Natera’s Signatera test provides a personalized measure of ctDNA that may complement radiologic assessment. Longitudinal ctDNA assessments may provide additional information in patients treated with AGX101, particularly when imaging shows metabolic or structural changes whose relationship to viable tumour is uncertain.
“We believe AGX101 has the potential to offer a differentiated therapeutic approach for patients with advanced solid tumours,” said Paul Jaminet, Ph.D., co-founder and CEO of Angiex. “This collaboration will allow us to evaluate whether longitudinal ctDNA measurements can complement imaging and improve our understanding of treatment response.”
“Signatera provides additional depth into early biologic response assessment that can meaningfully advance our understanding of this novel drug class,” said Eric Matthews, general manager, biopharma, at Natera. “We look forward to working with the Angiex team to generate molecular response data that can inform the development of AGX101 and advance this promising therapeutic approach.”
Natera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. The company aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives.
Angiex Inc. is a privately held biotechnology company focused on developing Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) for the treatment of solid cancers. Based in Cambridge, Mass., Angiex was founded by leading experts in angiogenesis, vascular biology, and oncology.
|